CD274 and neoplasm: Neoadjuvant/adjuvant immunotherapy is most likely to influence patient outcome when tumor cells are well recognized by the immune system but activation of immune checkpoints, either by tumor cells expressing PDL1 or as a physiological part of the immune response, is the main reason why tumor is not eliminated.